---
title: "Key facts: Novartis faces patent expirations; Citigroup issues 'buy' rating; Cosentyx selected for Medicare negotiations"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273918674.md"
description: "Novartis is facing revenue challenges due to impending patent expirations on key drugs and is exploring acquisitions of biotech firms to maintain a strong pipeline of protected intellectual property.1Citigroup has initiated a 'buy' rating on Novartis, citing the company as a 'consistent earnings outperformer' and noting the presence of several potential multi-billion-dollar drugs in its pipeline.2Novartis' psoriasis drug Cosentyx is among 15 drugs selected for Medicare price negotiations in 2028, part of the Inflation Reduction Act of 2022's third negotiation round.3"
datetime: "2026-01-28T02:03:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273918674.md)
  - [en](https://longbridge.com/en/news/273918674.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273918674.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273918674.md) | [繁體中文](https://longbridge.com/zh-HK/news/273918674.md)


# Key facts: Novartis faces patent expirations; Citigroup issues 'buy' rating; Cosentyx selected for Medicare negotiations

-   Novartis is facing revenue challenges due to impending patent expirations on key drugs and is exploring acquisitions of biotech firms to maintain a strong pipeline of protected intellectual property.1
-   Citigroup has initiated a 'buy' rating on Novartis, citing the company as a 'consistent earnings outperformer' and noting the presence of several potential multi-billion-dollar drugs in its pipeline.2
-   Novartis' psoriasis drug Cosentyx is among 15 drugs selected for Medicare price negotiations in 2028, part of the Inflation Reduction Act of 2022's third negotiation round.3

### 相关股票

- [SPDR S&P Health Equip (XHE.US)](https://longbridge.com/zh-CN/quote/XHE.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [NOVARTIS AG (NVS.US)](https://longbridge.com/zh-CN/quote/NVS.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)

## 相关资讯与研究

- [Novartis Agrees To Acquire Excellergy, Inc.](https://longbridge.com/zh-CN/news/280735969.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-CN/news/281346305.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/zh-CN/news/281517197.md)
- [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/zh-CN/news/281522861.md)
- [Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat](https://longbridge.com/zh-CN/news/281233412.md)